- Home
- NODK vs ARCT Comparison
NODK vs ARCT Comparison
Compare NODK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ARCT
- Stock Information
- Founded
- NODK 1946
- ARCT 2013
- Country
- NODK United States
- ARCT United States
- Employees
- NODK N/A
- ARCT N/A
- Industry
- NODK Property-Casualty Insurers
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- ARCT Health Care
- Exchange
- NODK Nasdaq
- ARCT Nasdaq
- Market Cap
- NODK 265.4M
- ARCT 373.7M
- IPO Year
- NODK 2017
- ARCT N/A
- Fundamental
- Price
- NODK $12.88
- ARCT $12.67
- Analyst Decision
- NODK
- ARCT Strong Buy
- Analyst Count
- NODK 0
- ARCT 8
- Target Price
- NODK N/A
- ARCT $52.83
- AVG Volume (30 Days)
- NODK 10.8K
- ARCT 386.5K
- Earning Date
- NODK 08-07-2025
- ARCT 08-11-2025
- Dividend Yield
- NODK N/A
- ARCT N/A
- EPS Growth
- NODK N/A
- ARCT N/A
- EPS
- NODK N/A
- ARCT N/A
- Revenue
- NODK $322,139,000.00
- ARCT $143,680,000.00
- Revenue This Year
- NODK N/A
- ARCT N/A
- Revenue Next Year
- NODK N/A
- ARCT $37.73
- P/E Ratio
- NODK $44.62
- ARCT N/A
- Revenue Growth
- NODK 3.15
- ARCT 15.38
- 52 Week Low
- NODK $12.01
- ARCT $8.04
- 52 Week High
- NODK $17.24
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- NODK 44.44
- ARCT 42.55
- Support Level
- NODK $13.04
- ARCT $12.75
- Resistance Level
- NODK $13.49
- ARCT $15.83
- Average True Range (ATR)
- NODK 0.27
- ARCT 0.88
- MACD
- NODK -0.04
- ARCT -0.14
- Stochastic Oscillator
- NODK 18.75
- ARCT 3.07
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.